InflaRx Doses First Patient in Multicenter Randomized Clinical Trial in Severe Progressed COVID-19 Pneumonia in Europe upon Receipt of Initial Positive Human Data with InflaRx’s anti-C5a Technology

Written by Petra Hegmann on 31st March 2020. Posted in Client News.

• Previous
• Next